Evaluating the access process for patients transitioning from intravenous to subcutaneous biologic administration for inflammatory bowel disease

Taylor Kissel, Miranda Murray, Josh DeClercq, Autumn Zuckerman

Open source

DOI
10.1093/crocol/otag087
Published
2026-07
Container
Crohn’s & Colitis 360
Publisher
Oxford University Press (OUP)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/crocol/otag087,
  title = {Evaluating the access process for patients transitioning from intravenous to subcutaneous biologic administration for inflammatory bowel disease},
  author = {Taylor Kissel and Miranda Murray and Josh DeClercq and Autumn Zuckerman},
  year = {2026},
  journal = {Crohn’s \& Colitis 360},
  doi = {10.1093/crocol/otag087},
  url = {https://doi.org/10.1093/crocol/otag087}
}

RIS

TY  - JOUR
TI  - Evaluating the access process for patients transitioning from intravenous to subcutaneous biologic administration for inflammatory bowel disease
AU  - Taylor Kissel
AU  - Miranda Murray
AU  - Josh DeClercq
AU  - Autumn Zuckerman
PY  - 2026
JO  - Crohn’s & Colitis 360
DO  - 10.1093/crocol/otag087
UR  - https://doi.org/10.1093/crocol/otag087
ER  - 

APA

Kissel, T., Murray, M., DeClercq, J., & Zuckerman, A. (2026). Evaluating the access process for patients transitioning from intravenous to subcutaneous biologic administration for inflammatory bowel disease. Crohn’s & Colitis 360. https://doi.org/10.1093/crocol/otag087

Source records